|
|
发表于 2020-8-27 18:35
来自手机
|显示全部楼层
此文章由 chier819 原创或转贴，不代表本站立场和观点，版权归 oursteps.com.au 和作者 chier819 所有！转贴必须注明作者、出处和本声明，并保持内容完整
小熊妈妈 发表于 2020-8-27 17:27
楼主，bit出ann啦
看这段就好了。：）
Coronavirus
Biotron’s core expertise lies in the design and development of drugs that target virus-encoded proteins known as viroporins. Viroporins are found in a broad range of viruses and play key roles in viral pathogenesis. Viroporins are central to viruses modifying host immune responses so that they can fly under the radar and establish and maintain ongoing cycles of infection. Biotron has designed and developed a library of compounds that target viroporins from a broad range of different viruses that cause serious infections in humans and other hosts.
Within Biotron’s anti-viroporin library are compounds that have shown good activity against a range of coronaviruses, based on studies that were undertaken at the time of outbreak of severe acute respiratory syndrome (SARS-1) – which was a coronavirus – back in 2002-2004. The Company’s scientists were the first to identify and publish data showing that the E protein of the coronavirus is a viroporin and a good target for antiviral drugs.
In February this year, Biotron began testing a range of its compounds against SARS-CoV-2, the causative agent of COVID-19, to assess whether they can inhibit this new coronavirus. This work is progressing well in a series of different assays are to assess impact of the compounds on markers of virus replication as well as immune markers. These assays will provide the best overall understanding of the potential of Biotron’s compounds to treat COVID-19.
Biotron remains focused on progressing its antiviral programs directed at viroporins through to a commercial outcome. The current pandemic highlights the importance of novel approaches such as Biotron’s with its potential to target a broad range of existing and emerging viruses.
|
|
在那木措湖边，我们四目凝望——周瑜传 (2005-12-20) 铁枪 
楼主:chier819
